Usefulness of Automated Hematology System Sysmex XN‐3100 for the Quantification of Schistocytes and Early Detection of the Underlying Thrombotic Microangiopathy

INTRODUCTION: Light microscopy is still the gold standard method for schistocyte counting in the blood smear. Some hematology analyzers can quantitatively determine fragmented red blood cells (FRC) as part of the full blood count. We examined the usefulness of two quantitative schistocyte methods on Sysmex XN-3100, comparing them with the standard reference method (SCHISTO-LM). METHODS: FRC count was performed by fluorescent flow cytometry in the reticulocyte channel. A locally designed method was applied on DI-60 digital morphology analyzer (SCHISTO-DI), allowing schistocyte quantification according to ICSH recommendations, using the RBC menu. FRC ≥ 1.0% and schistocytes > 2/high-power field were considered positive. Measurements were performed in 91 blood samples/peripheral blood smears of 54 patients with a suspicion of thrombotic microangiopathy (TMA). RESULTS: Significantly higher FRC (p = 0.004), SCHISTO-DI (p < 0.001), and SCHISTO-LM (p < 0.001) were found in TMA-positive patients compared to TMA-negative and patients in remission. Stratification of TMA-positive patients by TMA type revealed no significant differences for all tests. Both positive SCHISTO-LM and SCHISTO-DI were recorded in 15/91 samples (sensitivity = 100%, 95% CI = 78.2-100.0 and negative predictive value (NPV) = 100%, 95% CI = 94.4-100.0). False-negative FRC results were detected in 5/15 schistocyte-positive samples (sensitivity = 66.7%, 95% CI = 38.4-88.2; NPV = 92.9%, 95% CI = 86.3-96.4). The highest agreement was revealed between SCHISTO-DI and SCHISTO-LM (κ = 0.637). SCHISTO-DI demonstrated the best AUC for discrimination between TMA-positive and TMA-negative patients (0.942; 95% CI = 0.843-0.987), and similar AUC (0.818; 95% CI = 0.700-0.905) as SCHISTO-LM (0.820; 95% CI = 0.702-0.906) for discrimination between TMA-positive and patients with TTP/aHUS in remission. CONCLUSION: Despite the slightly lower sensitivity of FRC, the newly designed SCHISTO-DI method demonstrated excellent sensitivity and NPV for schistocyte detection, concordant with SCHISTO-LM results.

Authors

Institutions

Publication Details

Journal
International Journal of Laboratory Hematology
Published
2026-08-03
DOI
https://doi.org/10.1111/ijlh.70208
Primary Topic
Complement system in diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Usefulness of Automated Hematology System Sysmex XN‐3100 for the Quantification of Schistocytes and Early Detection of the Underlying Thrombotic Microangiopathy

Marija Miloš, Sunčica Ries, Désirée Coen Herak, Marijana Medić et al.
International Journal of Laboratory Hematology
Complement system in diseases
article

Usefulness of Automated Hematology System Sysmex XN‐3100 for the Quantification of Schistocytes and Early Detection of the Underlying Thrombotic Microangiopathy

Marija Miloš, Sunčica Ries, Désirée Coen Herak, Marijana Medić, Drazen Pulanic, Koraljka Gjadrov Kuveždić, Laura Matković
article en

Abstract

INTRODUCTION: Light microscopy is still the gold standard method for schistocyte counting in the blood smear. Some hematology analyzers can quantitatively determine fragmented red blood cells (FRC) as part of the full blood count. We examined the usefulness of two quantitative schistocyte methods on Sysmex XN-3100, comparing them with the standard reference method (SCHISTO-LM). METHODS: FRC count was performed by fluorescent flow cytometry in the reticulocyte channel. A locally designed method was applied on DI-60 digital morphology analyzer (SCHISTO-DI), allowing schistocyte quantification according to ICSH recommendations, using the RBC menu. FRC ≥ 1.0% and schistocytes > 2/high-power field were considered positive. Measurements were performed in 91 blood samples/peripheral blood smears of 54 patients with a suspicion of thrombotic microangiopathy (TMA). RESULTS: Significantly higher FRC (p = 0.004), SCHISTO-DI (p < 0.001), and SCHISTO-LM (p < 0.001) were found in TMA-positive patients compared to TMA-negative and patients in remission. Stratification of TMA-positive patients by TMA type revealed no significant differences for all tests. Both positive SCHISTO-LM and SCHISTO-DI were recorded in 15/91 samples (sensitivity = 100%, 95% CI = 78.2-100.0 and negative predictive value (NPV) = 100%, 95% CI = 94.4-100.0). False-negative FRC results were detected in 5/15 schistocyte-positive samples (sensitivity = 66.7%, 95% CI = 38.4-88.2; NPV = 92.9%, 95% CI = 86.3-96.4). The highest agreement was revealed between SCHISTO-DI and SCHISTO-LM (κ = 0.637). SCHISTO-DI demonstrated the best AUC for discrimination between TMA-positive and TMA-negative patients (0.942; 95% CI = 0.843-0.987), and similar AUC (0.818; 95% CI = 0.700-0.905) as SCHISTO-LM (0.820; 95% CI = 0.702-0.906) for discrimination between TMA-positive and patients with TTP/aHUS in remission. CONCLUSION: Despite the slightly lower sensitivity of FRC, the newly designed SCHISTO-DI method demonstrated excellent sensitivity and NPV for schistocyte detection, concordant with SCHISTO-LM results.

International Journal of Laboratory Hematology
University Hospital Centre Zagreb (HR), University of Mostar (BA), University of Zagreb (HR)
Openalex Percentile: Top 15%
Complement system in diseases
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.